₹ 10.8 Cr
Volume transacted
537.7 K
stocks traded
Last Updated time: 25 Jul 9.00 AM
Marksans Pharma Ltd
NSE: MARKSANS
PE
29.1
Last updated : 25 Jul 9.00 AM
The P/E Ratio of Marksans Pharma Ltd is 29.1 as of 25 Jul 9.00 AM .a1#The P/E Ratio of Marksans Pharma Ltd changed from 13.3 on March 2019 to 12 on March 2023 . This represents a CAGR of -2.04% over 5 years. a1#The Latest Trading Price of Marksans Pharma Ltd is ₹ 201.1 as of 25 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.3 to 27.3 in 5 years. This represents a CAGR of -0.72%a1# The PE Ratio of Automobile industry is 18.9. The PE Ratio of Finance industry is 23.5. The PE Ratio of IT - Software industry is 29.1. The PE Ratio of Pharmaceuticals industry is 38.6. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 24.3. In 2024a1#The Market Cap of Marksans Pharma Ltd changed from ₹ 1017 crore on March 2019 to ₹ 3194 crore on March 2023 . This represents a CAGR of 25.72% over 5 years. a1#The Revenue of Marksans Pharma Ltd changed from ₹ 450.27 crore to ₹ 576.54 crore over 8 quarters. This represents a CAGR of 13.16% a1#The EBITDA of Marksans Pharma Ltd changed from ₹ 89.36 crore to ₹ 126.17 crore over 8 quarters. This represents a CAGR of 18.82% a1#The Net Pr of Marksans Pharma Ltd changed from ₹ 60.18 crore to ₹ 77.64 crore over 8 quarters. This represents a CAGR of 13.58% a1#The Dividend Payout of Marksans Pharma Ltd changed from 4.69 % on March 2019 to 22.03 % on March 2023 . This represents a CAGR of 36.26% over 5 years. a1#
Open Demat Account
Enter your mobile no. to continue
+91
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Period | |
---|---|
Mar '19 | 13.3 |
Mar '20 | 4.7 |
Mar '21 | 8.7 |
Mar '22 | 10.1 |
Mar '23 | 12 |
Market Cap
₹ 9,113 Cr
EPS
₹ 6.9
P/E Ratio (TTM) *
29.1
P/B Ratio (TTM) *
4.4
Day’s High
₹ 211.8
Day’s Low
₹ 199.1
DTE *
0.1
ROE *
15.2
52 Week High
₹ 211.8
52 Week Low
₹ 93.85
ROCE *
18.8
* All values are consolidated
Last Updated time: 25 Jul 9.00 AM
* All values are consolidated
Last Updated time: 25 Jul 9.00 AM
Marksans Pharma Ltd
NSE: MARKSANS
PRICE
₹ 201.1
-4.25 (-2.07%)
Last updated : 25 Jul 15:30
The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.
1M
1Y
3Y
5Y
* All values are in Rupees
Strength
2
S
Weakness
1
W
Opportunity
0
O
Threats
1
T
Market Value
₹ 9,113
Asset Value
₹ 1,687
4.4 X
Value addition
* All values are in Rupees
Company Name | PE | Market Cap (INR Cr.) |
---|---|---|
Marksans Pharma Ltd | 29 | 9,113 |
Sun Pharmaceuticals Industries Ltd | 40 | 399,537 |
Zydus Lifesciences Ltd | 31 | 121,312 |
Cipla Ltd | 28 | 121,120 |
Divis Laboratories Ltd | 75 | 120,782 |
Dr Reddys Laboratories Ltd | 20 | 114,348 |
Earnings
₹313 Cr
29.1 X
PE Ratio
Market Cap
₹9113Cr
PE Ratio
PS Ratio
PB Ratio
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.
P/E ratio = (CMP of share/ Earning per share)
1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Earnings
₹313 Cr
29.1 X
PE Ratio
Market Cap
₹9113Cr
PE Ratio
PS Ratio
PB Ratio
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.
P/E ratio = (CMP of share/ Earning per share)
1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Period | |
---|---|
Mar '19 | 1017 |
Mar '20 | 569 |
Mar '21 | 2045 |
Mar '22 | 1864 |
Mar '23 | 3194 |
* All values are a in ₹crore
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.
Period | |
---|---|
Jun '22 | 450 |
Sep '22 | 467 |
Dec '22 | 497 |
Mar '23 | 497 |
Jun '23 | 510 |
Sep '23 | 550 |
Dec '23 | 591 |
Mar '24 | 577 |
* All values are a in ₹crore
PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.
Period | |
---|---|
Jun '22 | 89 |
Sep '22 | 94 |
Dec '22 | 94 |
Mar '23 | 121 |
Jun '23 | 112 |
Sep '23 | 133 |
Dec '23 | 138 |
Mar '24 | 126 |
* All values are a in ₹crore
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue
Period | |
---|---|
Jun '22 | 60 |
Sep '22 | 60 |
Dec '22 | 62 |
Mar '23 | 83 |
Jun '23 | 70 |
Sep '23 | 84 |
Dec '23 | 83 |
Mar '24 | 78 |
* All values are a in ₹crore
Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.
Period | |
---|---|
Mar '19 | 5 |
Mar '20 | 11 |
Mar '21 | 10 |
Mar '22 | 10 |
Mar '23 | 22 |
* All values are a in %
Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982. Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited with effect from 10th October, 2005. The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation. The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai. In 2004-05, the Company amalgamated with M/s. Marksans Pharma Limited (formerly M/s. Glenmark Laboratories Limited) pursuant to High Court order dated 19th August, 2005. As provided in the approved Scheme of Amalgamation, necessary shares were issued to the shareholders of the M/s. Marksans Pharma Limited (formerly M/s. Glenmark Laboratories Limited). The Company acquired majority stake in Nova Pharmaceuticals Australasia Private Limited in 2005; further, it acquired two companies, Bell Sons & Company (Druggists) Limited and Relonchem Limited in the UK in 2008. The Company received first ANDA approval in the USA in 2011. It acquired Time-Cap Laboratories Inc. in the US in 2015. The Company launched the CNS-Cerebella division in FY 2017-18. It launched soft gelatin capsules, a niche category, Launched two products and received CRL for 4 ANDAs for approval with the USFDA. The Company commissioned a new R&D center at Navi Mumbai, apart from one in Goa in 2019-20. The Company acquired the business of Tevapharm India Private Limited relating to the manufacture and supply of pharmaceutical formulations in Verna, Goa as a going concern on a slump sale in April, 2023.
Marksans Pharma arm receives UK MHRA approval for four products
Marksans Pharma announced that its wholly owned subsidiary, Relonchem has received marketi...
Read more
02 Jul 202413:41
Board of Marksans Pharma recommends final dividend
Marksans Pharma announced that the Board of Directors of the Company at its meeting held o...
Read more
30 May 202416:01
Marksans Pharma declines after Q4 PAT slides 6% YoY to Rs 78 cr
Revenue from operations jumped 15.23% YOY to Rs 560.01 crore in Q4 FY24, driven by volume ...
Read more
30 May 202414:37
Marksans Pharma arm receives UK MHRA marketing authorization for Levetiracetam Relonchem
Marksans Pharma announced that its wholly owned subsidiary, Relonchem has received marketi...
Read more
28 May 202412:08
Marksans Pharma declare Quarterly Result
Marksans Pharma will hold a meeting of the Board of Directors of the Company on 30 May 202...
Read more
13 May 202415:04
Marksans Pharma's Goa unit concludes USFDA inspection with observations
Marksans Pharma announced that a routine current Good Manufacturing Practices (cGMP) inspe...
Read more
18 Apr 202411:45
FAQs for PE of Marksans Pharma Ltd
What is Marksans Pharma Ltd current share price?
What is Marksans Pharma Ltd's market cap?
What are Marksans Pharma Ltd's total net assets?
Is Marksans Pharma Ltd making a profit or loss?
Unlimited trading at just
Rs. 199